OrbiMed
China biotech player Gracell raises $100m Series C
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
Lee's Pharmaceutical spin-out gets $145m Series B
Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO), a subsidiary of Lee’s Pharmaceutical, has raised a $145 million Series B round led by Hillhouse Capital and TPG Asia.
China's InventisBio secures $147m Series D
GL Ventures, the China venture capital arm of Hillhouse Capital, has led a $147 million Series D round for Shanghai-based biotech developer InventisBio.
Hillhouse leads $418m investment in China's I-Mab
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
China cancer test kit provider gets $30m Series E
New Horizon Health, a China-based manufacturer of cancer testing kits for use at home, has raised $30 million in a Series E round of funding led by Rock Springs Capital.
China’s Harbour BioMed raises $103m Series C
Chinese biotech start-up Harbour BioMed has raised $102.8 million in Series C funding. It comes four months after it closed an extended Series B round of $75 million.
Zentalis raises $20m for China drug development venture
Zentalis Pharmaceuticals, a US cancer treatment specialist that raised $165 million in an IPO last month, has secured $20 million in funding to establish a China-based joint venture.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
OrbiMed targets $750m for Asia healthcare fund
US-based healthcare investment firm OrbiMed has launched its fourth Asian private equity fund with a view to raising $750 million.
Advent buys Indian biopharma player
Advent International has agreed to acquire a controlling position in Bharat Serums and Vaccines, an Indian biopharmaceuticals supplier focused on the women’s health segment.
Chinese antibody drug developer raises $150m
Akeso Biopharma, a Chinese biotech company specializing in antibody drugs, has raised a $150 million Series D round led by Loyal Valley Capital and Sino Biopharm.
PE-backed Hansoh Pharma completes $1b Hong Kong IPO
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Hillhouse-backed CRO Frontage raises $205m in HK IPO
Frontage Holdings, a China-based contract research organization (CRO), has raised HK$1.61 billion ($205.1 million) in its Hong Kong IPO, having received support from several private equity investors.
Advantech, CMBI lead Series C for China's InventisBio
Advantech Capital and CMB International, an investment unit of China Merchants Bank, have led a $70 million Series C funding round for InventisBio, a Chinese clinical stage biotech company.
US, China-based Apollomics raises $100m Series B
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
China's Alphamab gets $100m Series A
China’s Alphamab Oncology has completed a $100 million Series A funding round from a group of investors including PAG Growth Capital, Advantech Capital, and OrbiMed.
Hillhouse co-leads $93m Series B for US biotech firm
Hillhouse Capital and Quan Capital have led a $93 million Series B round for NextCure, a US-based biopharmaceutical company focused on cancer and other diseases.
China PE outlook: End of the party
Growth stage technology deals have retained a strong following in 2018, but elsewhere in Chinese private equity the mood is more somber
US, China-based Terns Pharma secures $80m Series B
Vivo Capital and Orbimed have co-led an $80 million Series B funding round for US and China-based Terns Pharmaceuticals.
China biotech: Finding the formula
An eruption of investment and company creation in Chinese biotech has signaled the dawn of a raw but promising market. First-movers must negotiate immediate pitfalls while targeting long-term upside
SeaLink leads $29m round for Indian children’s hospital
SeaLink Capital Partners has led a INR2 billion ($29 million) investment in Indian maternal and pediatric hospital chain Surya Children’s Medicare, providing an exit for OrbiMed Advisors.
Lilly Asia leads $25m round for US-based Avedro
Lilly Asia Ventures (LAV) has led a $25 million round for Avedro, a US-based ophthalmic pharmaceutical and medical devices company with a view to expanding in Asia.
Cathay Capital, OrbiMed sell Echosens stakes to Astorg
Cathay Capital Private Equity and OrbiMed have exited Echosens, a France-based medical diagnostic equipment company owned by China’s Inner Mongolia FuRui Medical Science, to European PE firm Astorg.
OrbiMed re-ups in India's Vivimed Labs
OrbiMed has invested a further $7.5 million in the active pharmaceutical ingredient (API) unit of India-listed drug maker Vivimed Labs.